Cipla secures USFDA approval for pancreatic disease injection, shares surge

Mumbai (Maharashtra) [India], May 22 (ANI): Mumbai-headquartered pharma major, Cipla’s US arm has secured final approval from the United States Food and Drug Administration (USFDA) for its Lanreotide Injection 120 mg/0.5 mL, 90 mg/0.3 mL, and 60 mg/0.2 mL.
The injection, pre-filled and ready to use, is an AP-rated therapeutic generic version of Somatuline Depot injection used in the treatment of patients with Acromegaly a

Source link